Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...
Zacks.com on MSN
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
Biotech bigwig Gilead Sciences, Inc. GILD is scheduled to report third-quarter 2025 result s on Oct. 30, after market close.
South Africa's Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...
AllAfrica on MSN
South Africa: Lenacapavir - a Game-Changer in South Africa's HIV Prevention Strategy
When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in January this year, we immediately set about finding solutions. Among the most pressing was to ...
This marks a major milestone in the country’s fight against new infections. In this groundbreaking move, Eswatini has become ...
This cooperation aims to expedite access to advanced medicines and vaccines developed by GSK, particularly by bringing to ...
Contraception and family planning are vital aspects of sexual and reproductive health and rights. Despite major advances in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback